FDA Approves Abbott's (ABT) Drug Coated Stent, XIENCE
More News related to ABT
- Morgan Stanley Resumes Abbott Labs (ABT) at Overweight
- Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year
- Zimmer Holdings (ZMH) Acquires Abbott's Spine Business
- Proxy Group Reacts to Recent Stock Activity in Artes Medical, Inc.
- Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania
More News related to Corporate News
- The Report Contains Up-to-Date Analysis of Best-Practice, Developments and Emerging Trends in Biometrics
- This 2008 U.S. Lawn and Garden Supplies Product Lines Report Provides the Most Current and Accurate Estimates of the Product Lines and their Distribution Channels
- An Essential and Comprehensive Report on Biopharmaceuticals in the US and European Markets
- Wellness Program Return-on-Investment: Benchmarks, Strategies, and Case Studies for Proving the Value of Your Wellness Initiatives Conference CD-ROM
- CeCors Inc. Announces World's First 10 Terabit Carrier Class Ethernet Multi-Layer Switch
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.
The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
Related Categories
Corporate NewsFDA
Hot List
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
